Summary: A new study reports a notable association between glucosamine, a widely used over-the-counter joint supplement, and faster cognitive decline. Researchers combined artificial intelligence analysis of 12 years of deidentified electronic health records with advanced spatial molecular analysis of post-mortem human brain tissue and controlled animal experiments to investigate potential mechanisms.
Key Facts
- Widespread use and brain access: Glucosamine is commonly taken by millions of older adults for arthritis and joint pain. The compound crosses the blood–brain barrier, allowing it to interact directly with brain metabolism.
- Large-scale 12-year AI record review: Investigators used artificial intelligence to analyze deidentified medical records from a major health system covering 2012–2024. They found that about 8% of patients diagnosed with mild cognitive impairment (MCI) or Alzheimer’s and related dementias (ADRD) reported using glucosamine.
- Higher risk of dementia progression: After adjusting for age, sex and demographic factors, glucosamine use was associated with a roughly 25% greater likelihood of progressing from MCI to Alzheimer’s disease in the retrospective dataset.
- Increased short-term mortality in established dementia: Among patients already diagnosed with ADRD, glucosamine use correlated with a roughly 25% increase in short-term mortality risk. No similar mortality increase was observed in the MCI group, suggesting established Alzheimer’s disease may be uniquely vulnerable to this metabolic stress.
- Metabolic mechanism — hyperglycosylation: Spatial molecular techniques revealed that Alzheimer’s brains exhibit an overactive protein glycosylation (sugar-tagging) pathway. While normal glycosylation helps proteins fold and function, excessive glycan addition appears to impair cellular machinery in vulnerable brains.
- Animal and human tissue validation:
- Mice: In genetically modified Alzheimer’s-model mice, glucosamine administration increased protein glycosylation and produced deficits in social recognition memory. Chemical inhibition of the glycan-attachment pathway reversed those cognitive deficits.
- Human brain tissue: Post-mortem samples from a brain bank showed markedly elevated glycosylation signatures in confirmed Alzheimer’s cases compared with non-diseased controls.
- Implications for treatment: These results position altered glycan metabolism as an active driver of neurodegeneration and a potential therapeutic target that could complement efforts aimed at amyloid-beta and tau pathology.
Source: University of Florida
Researchers at the University of Florida report that glucosamine supplementation is associated with an increased risk of progression from mild cognitive impairment to Alzheimer’s disease and with higher short-term mortality among patients with established dementia. The conclusions come from a combination of retrospective electronic health record analysis, spatial molecular profiling of human brain samples, and mechanistic studies in animal models.
“In the United States, roughly 7 million people live with Alzheimer’s disease, and many more have related dementias,” said Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation at the McKnight Brain Institute. “Many people with cognitive impairment take over-the-counter supplements, and our data suggest these could unintentionally worsen disease progression in vulnerable brains.”
To explore this concern, Sun and colleagues—working with collaborators Yi Guo, Ph.D., and Jiang Bian, Ph.D.—applied artificial intelligence tools to deidentified medical records spanning 2012–2024, identifying thousands of patients with MCI or ADRD. After statistical adjustment, the researchers observed the association between glucosamine use and the increased odds of MCI progressing to dementia, as well as higher mortality in patients with established ADRD.
Using cutting-edge spatial metabolomics, lipidomics and glycomics developed in Sun’s laboratory, the team characterized molecular changes in brain tissue. They found that Alzheimer’s brains display widespread hyperglycosylation—excessive addition of sugar structures to proteins—driven by increased glycan biosynthesis. In mouse models, oral glucosamine increased glycan attachment to proteins and worsened cognitive measures, while reducing glycan biosynthesis improved outcomes.
Matt Gentry, Ph.D., chair of the Department of Biochemistry and Molecular Biology and a study co-author, emphasized that the electronic health record findings are associative and do not prove causation. “The statistical link is compelling and aligns with mechanistic data from tissues and animal experiments,” Gentry noted, “but clinical trials are required to establish causality and guide practice.”
The researchers suggest clinicians and patients discuss supplement use in the context of cognitive risk. For people with MCI or a family history of dementia, the findings recommend careful review of glucosamine use with healthcare providers until further evidence from controlled human trials is available.
Key Questions Answered:
A: No. The study shows a strong statistical association supported by molecular and animal model data, but it does not establish direct causation. The authors call for formal clinical trials to confirm these findings.
A: Glucosamine crosses the blood–brain barrier and enters metabolic pathways that build complex sugar structures on proteins. In Alzheimer’s-affected brains, this glycosylation pathway appears overactive, which can disrupt protein function and cellular processes.
A: This study is not a clinical directive. Patients who take glucosamine—particularly those with MCI, diagnosed dementia, or a family history of Alzheimer’s—should discuss its risks and benefits with their healthcare provider before making changes.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context was added by staff to aid reader understanding.
About this Alzheimer’s disease research news
Author: Mickie Anderson
Source: UF Health
Contact: Mickie Anderson – UF Health
Image credit: Neuroscience News
Original Research: Open access. “Hyperglycosylation is a metabolic driver of Alzheimer’s disease.” Authors include Tara R. Hawkinson, Zizhen Liu, Roberto A. Ribas and colleagues, with senior author Ramon C. Sun. Journal: Nature Metabolism. DOI: 10.1038/s42255-026-01538-4
Abstract (summary)
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive decline. While metabolic changes are commonly observed in affected brains, their causal role has been unclear. This study identifies hyperglycosylation—excessive glycan addition to proteins—as a metabolic driver of Alzheimer’s disease. By integrating spatial metabolomics, lipidomics and glycomics across transgenic mouse models and human post-mortem samples, and using isotopic tracing of N-linked glycans, the authors show that increased glycan biosynthesis produces a conserved hyperglycosylation phenotype in Alzheimer’s. Genetic suppression of glycan biosynthetic enzymes improved cognition in mouse models, whereas oral glucosamine worsened outcomes. Retrospective electronic health record analysis supports an association between glucosamine supplementation and accelerated disease progression and poorer survival in patients with Alzheimer’s. These results point to glycan metabolism as an actionable target for future therapeutic development.